<?xml version='1.0' encoding='utf-8'?>
<document id="29667438"><sentence text="The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia."><entity charOffset="72-81" id="DDI-PubMed.29667438.s1.e0" text="potassium" /></sentence><sentence text="Hyperkalemia (HK) occurs often among patients with chronic kidney disease (CKD) and heart failure (HF) and those treated with renin-angiotensin-aldosterone system inhibitors (RAASI)" /><sentence text=" Even small deviations from normal potassium levels carry increased risk of mortality"><entity charOffset="35-44" id="DDI-PubMed.29667438.s3.e0" text="potassium" /></sentence><sentence text=" Patiromer is approved for treatment of HK and has been shown in clinical trials to reduce serum potassium among patients with HK and comorbid conditions"><entity charOffset="97-106" id="DDI-PubMed.29667438.s4.e0" text="potassium" /></sentence><sentence text=" Areas covered: We review pooled data from two clinical trials of patiromer in patients with CKD and HK, safety of patiromer in special populations, drug-drug interaction (DDI) studies, and other studies in healthy volunteers" /><sentence text=" Expert opinion: Potassium must be maintained within a narrow range to avoid increased risk of mortality"><entity charOffset="17-26" id="DDI-PubMed.29667438.s6.e0" text="Potassium" /></sentence><sentence text=" Patients with CKD and HF and those receiving RAASI require careful monitoring of potassium levels"><entity charOffset="82-91" id="DDI-PubMed.29667438.s7.e0" text="potassium" /></sentence><sentence text=" Patiromer effectively reduces serum potassium, and gastrointestinal adverse events (AEs) are the most common patiromer-associated AEs"><entity charOffset="37-46" id="DDI-PubMed.29667438.s8.e0" text="potassium" /></sentence><sentence text=" Effective management of HK with patiromer may allow use of RAASI at optimal doses as recommended by treatment guidelines" /><sentence text=" Future research should examine the potential for potassium binders, including patiromer, to extend use of RAASI in appropriate patient populations"><entity charOffset="50-59" id="DDI-PubMed.29667438.s10.e0" text="potassium" /></sentence><sentence text="" /></document>